C12Y 204/01144
Beta-1,4-mannosyl-glycoprotein 4-beta-n-acetylglucosaminyltransferase
Official title: Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (2.4.1.144)
C12Y204/01144 (Beta-1,4-mannosyl-glycoprotein 4-beta-n-acetylglucosaminyltransferase) appears on 6 US grants and 15 published applications in this corpus.
Search patents in C12Y- Granted patents
- 6
- Published applications
- 15
- Assignees
- 8
- Inventors
- 28
- Latest grant
- 13 Aug 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 2 | 1 |
| 2015 | 1 | 1 |
| 2016 | 1 | 4 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 2 |
By publication year.
Recent patents
- Viral resistant cells and uses thereof13 Aug 2019US 10,377,990 B2Sigma-Aldrich Co.
- Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function29 Mar 2016US 9,296,820 B2Roche Glycart AG
- Method to engineer mammalian-type carbohydrate structures13 Jan 2015US 8,932,825 B2GlycoFi, Inc.
- Antigen binding molecules with increased Fc receptor binding affinity and effector function11 Nov 2014US 8,883,980 B2Roche Glycart AG
- Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function14 Oct 2014US 8,859,234 B2Roche Glycart AG
- Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof10 Jul 2025US 2025/0223364 A1Dren Bio, Inc.
- Bisected trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them5 Jun 2025US 2025/0177424 A1Cer Groupe
- Antigen binding molecules with increased fc receptor binding affinity and effector function12 Sep 2024US 2024/0301079 A1Roche Glycart AG
- Antigen binding molecules with increased fc receptor binding affinity and effector function6 Jul 2023US 2023/0212303 A1Roche Glycart AG
- Antigen binding molecules with increased fc receptor binding affinity and effector function7 Jan 2021US 2021/0002382 A1Roche Glycart AG
Most cited
By later US patents
- Method to engineer mammalian-type carbohydrate structures15US 8,932,825 B2GlycoFi, Inc. · 2015
- Antigen binding molecules with increased Fc receptor binding affinity and effector function11US 8,883,980 B2Roche Glycart AG · 2014
- Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function11US 9,296,820 B2Roche Glycart AG · 2016
- Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function5US 8,367,374 B2Roche Glycart AG · 2013
- Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function3US 8,859,234 B2Roche Glycart AG · 2014